SOPHiA GENETICS SA Ordinary Shares - SOPH STOCK NEWS

SOPHiA GENETICS (Nasdaq: SOPH) will release its financial results for Q1 2023 on May 9, 2023, prior to market opening. This announcement marks a significant engagement for stakeholders, as the company plans to host a conference call at 8:00 a.m. EDT to discuss its performance and future business outlook. The session will be accessible via the company’s Investor Relations website, with a replay available afterward. SOPHiA GENETICS is focused on data-driven medicine and utilizes its cloud-native SOPHiA DDM™ Platform to analyze complex data sets for healthcare applications.

SOPHiA GENETICS (NASDAQ: SOPH) has partnered with the University of Maryland Medical Center (UMMC) to enhance rare disease research through its SOPHiA Whole Exome Solution™ v2. This next-generation sequencing (NGS) application streamlines data analysis, which is crucial for the detection and treatment of rare diseases affecting over 30 million people in the U.S. The implementation of this technology will aid UMMC in characterizing genetic variants, including mitochondrial mutations, which are vital for understanding inherited disorders. The SOPHiA DDM™ Platform complements this solution, utilizing AI and machine learning for efficient data interpretation, benefiting the rare disease community.

SOPHiA GENETICS (NASDAQ: SOPH) has partnered with Krsnaa Diagnostics, India's largest diagnostic services provider, to utilize its SOPHiA DDM™ for Hereditary Cancers Solution. This collaboration aims to enhance Krsnaa's next-generation sequencing (NGS) services, allowing for better detection and analysis of hereditary cancers impacting 10% of cancer cases. The technology leverages artificial intelligence and machine learning to streamline genomic evaluations, enabling healthcare providers to offer improved, accessible, and high-quality NGS tests. SOPHiA GENETICS emphasizes its commitment to democratizing data-driven medicine, supporting Krsnaa's mission in India. This partnership is expected to strengthen SOPHiA's presence in the growing market for NGS in cancer diagnostics.

SOPHiA GENETICS announced that Tel Aviv Sourasky Medical Center will implement the SOPHiA DDM™ HRD Solution to enhance its cancer research capabilities. This solution will aid in identifying patients with homologous recombination deficiency (HRD), a common trait in high-grade serous ovarian cancer and other cancers, potentially predicting therapy response. The technology offers decentralized data ownership and utilizes deep learning for improved genomic insights. The move is positioned to strengthen clinical decisions and optimize workflows at the medical center for advanced cancer treatments.

SOPHiA GENETICS (Nasdaq: SOPH) has partnered with Acutis Diagnostics to develop a new genomic assay using SOPHiA DDM™, aimed at enhancing patient enrollment in clinical oncology trials. This next-generation sequencing (NGS) test will leverage Acutis Diagnostics’ laboratory technologies and is designed to provide valuable insights for clinical researchers. By improving genomic screening capabilities, the assay aims to facilitate better clinical outcomes for cancer patients, many of whom have a hereditary cancer background. The collaboration underscores SOPHiA GENETICS' commitment to advancing data-driven medicine in oncology.

SOPHiA GENETICS (NASDAQ: SOPH) has announced a collaboration with Agilent to enhance cancer biomarker analysis. The integration of the SOPHiA DDM™ Platform with Agilent's SureSelect Cancer Comprehensive Genomic Profiling Assay Kit will facilitate the identification of multiple biomarkers in cancer research, helping clinical labs improve efficiency and access critical data. This partnership aims to democratize data-driven medicine through advanced analytics and reporting capabilities. The collaboration is currently being tested with TomaLab, a major lab in Italy.

SOPHiA GENETICS reported strong financial results for Q4 and full-year 2022, with total revenue reaching $47.6 million, up 18% year-over-year. Q4 revenue was $13.4 million, a 22% increase from Q4 2021. Excluding COVID-19 revenues, constant currency growth was 39% and 44% respectively. Gross margins hit a record 72% in Q4, while operating losses improved for the third consecutive quarter to $15.1 million. For 2023, SOPHiA guided revenue growth at or above 30% and announced expanded partnerships with AstraZeneca and Qiagen, enhancing its oncology capabilities.